{
  "id": "lynch-syndrome",
  "title": "Lynch Syndrome",
  "lang": "en",
  "source_lang": "en",
  "summary": "Lynch syndrome is an inherited cancer predisposition caused by defective DNA mismatch repair, chiefly increasing colorectal and endometrial cancer risks.",
  "category": "health",
  "subcategory": "diseases",
  "type": "concept",
  "aliases": [
    "Hereditary nonpolyposis colorectal cancer",
    "HNPCC",
    "Lynch cancer family syndrome"
  ],
  "generated_at": "2026-11-02",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/lynch-syndrome/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/lynch-syndrome/",
      "json": "https://aiwiki.page/zh/lynch-syndrome.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Lynch syndrome is an inherited predisposition to cancer caused by a constitutional defect in the DNA mismatch repair system. It most prominently increases the risks of colorectal cancer and endometrial cancer, while also increasing susceptibility to several other malignancies. Most affected families carry a pathogenic variant in one of four repair genes—MLH1, MSH2, MSH6, or PMS2—or a deletion involving EPCAM that silences neighboring MSH2. Having Lynch syndrome means having an increased probability of developing particular cancers, not having cancer itself.\n\nThe syndrome is among the most common inherited cancer predispositions and accounts for approximately 2–4% of colorectal cancers and about 3% of endometrial cancers. Its identification has consequences beyond the person initially diagnosed: relatives may share the inherited predisposition, and tumor mismatch repair status can affect treatment selection. Risks differ substantially by gene, age, sex, and family history, making Lynch syndrome a group of related, gene-specific conditions rather than a uniform clinical disorder.\n\nThe historical name “hereditary nonpolyposis colorectal cancer” distinguishes the syndrome from inherited conditions characterized by hundreds of intestinal polyps. That name is incomplete, however, because Lynch syndrome includes important cancers outside the colon and rectum, and because colorectal adenomas can still occur."
    },
    {
      "heading": "Historical recognition and population distribution",
      "text": "The earliest well-known description arose from the American pathologist Aldred Scott Warthin’s investigation of a family with an unusual concentration of cancers. His 1913 report described what became known as “Family G,” in which gastrointestinal and uterine cancers occurred across generations. Beginning in the 1960s, physician Henry T. Lynch and collaborators documented additional families and established that their pattern represented a heritable cancer predisposition rather than simply shared environmental exposure. The subsequent recognition of multiple associated cancer sites helped distinguish the syndrome from an exclusively colorectal disorder.\n\nBefore molecular testing became available, identification depended heavily on family structure. The 1991 Amsterdam criteria required at least three relatives with colorectal cancer, involvement of two successive generations, and at least one diagnosis before age 50, together with other conditions. The 1999 Amsterdam II criteria expanded the relevant cancers to include endometrial, small-bowel, ureteric, and renal-pelvis malignancies. These criteria were valuable for standardizing research families, but they were not sufficiently sensitive to identify all affected people. Small families, incomplete medical histories, early deaths from unrelated causes, and lower-penetrance variants could all obscure the inherited pattern.\n\nThe molecular basis emerged in the early 1990s through linkage studies, observations of unstable repetitive DNA in tumors, and identification of human repair genes related to those already studied in microorganisms. Discoveries involving MSH2 and MLH1 were followed by characterization of MSH6, PMS2, and the role of EPCAM deletions. These findings changed the syndrome from a pedigree-defined category into a molecularly identifiable condition.\n\nPopulation estimates suggest that roughly one person in 300 carries a pathogenic variant associated with Lynch syndrome, although estimates vary with the population and methods studied. Most carriers have not been recognized through routine clinical care. Population-based studies also indicate that MSH6 and PMS2 variants are more common than their representation in older, highly selected cancer-family series suggested. Their generally lower or later cancer risks help explain why family-history criteria missed many carriers.\n\nThe epidemiology of Lynch syndrome is strongly affected by ascertainment. Early studies preferentially enrolled families with numerous young cancer cases, producing higher risk estimates than some subsequent population-based investigations. Prospective registries have improved estimates by following identified carriers over time, but their participants commonly undergo surveillance, which itself changes observed cancer occurrence and outcomes. Founder variants can also produce unusually high local frequencies in particular populations. Consequently, a single worldwide prevalence or lifetime cancer-risk figure cannot fully describe the syndrome."
    },
    {
      "heading": "Mismatch repair failure and tumor development",
      "text": "DNA mismatch repair corrects errors that escape proofreading during DNA replication. These include incorrectly paired bases and small insertion–deletion loops. The MSH2–MSH6 protein complex recognizes many such abnormalities, while the MLH1–PMS2 complex coordinates subsequent repair. Other repair proteins remove the affected DNA segment and replace it using the opposite strand as a template. Failure of this process permits replication errors to accumulate across repeated cell divisions.\n\nThe inherited defect usually affects one copy of a repair gene. Most nonmalignant cells retain a functioning second copy and therefore maintain substantial repair capacity. A susceptible cell can acquire a second event that inactivates the remaining functional copy, through another mutation, loss of chromosomal material, or altered gene regulation. This corresponds to the two-hit model of tumor-suppressor gene inactivation. It explains how a predisposition inherited throughout the body can produce individual tumors at particular anatomical sites and times.\n\nAn important consequence is microsatellite instability, or MSI. Microsatellites are short, repeated DNA sequences that are especially prone to replication slippage. Without effective mismatch repair, their lengths change. When such repeats occur within protein-coding regions, insertions or deletions can shift the reading frame and disrupt genes involved in growth control, programmed cell death, and other functions. Mismatch repair-deficient tumors commonly acquire numerous mutations, although the precise pattern differs among tumors and among underlying repair defects.\n\nThe abnormal proteins produced by these mutations can generate new peptide sequences recognizable by the immune system. This helps explain both the prominent lymphocyte infiltration observed in many mismatch repair-deficient tumors and their susceptibility to certain forms of cancer immunotherapy. High tumor mutational burden and microsatellite instability are related features, but they are not interchangeable measurements. Tumors can have high mutation burdens for reasons unrelated to Lynch syndrome, and laboratory classification depends on the assay used.\n\nThe EPCAM mechanism illustrates that a gene need not encode a repair protein to cause the syndrome. Certain deletions at the end of EPCAM permit transcription to extend into neighboring MSH2, inducing methylation and silencing of its promoter in relevant tissues. Rare constitutional methylation of MLH1, termed a constitutional epimutation, can also produce a Lynch syndrome phenotype. Its inheritance may differ from that of a conventional DNA sequence variant.\n\nMismatch repair deficiency is not synonymous with Lynch syndrome. Many sporadic colorectal and endometrial cancers acquire MLH1 promoter methylation only within the tumor. Others develop two acquired pathogenic alterations in a repair gene without an inherited defect. Separating constitutional predisposition from tumor-limited repair failure is therefore central to accurate classification."
    },
    {
      "heading": "Cancer spectrum and gene-specific risks",
      "text": "Colorectal cancer is the best-known manifestation, but its likelihood is not uniform across Lynch syndrome genes. Published estimates to approximately age 80 commonly place colorectal cancer risk around 40–60% for MLH1 and MSH2 carriers, with generally lower risks for MSH6 and especially PMS2. Exact figures vary by sex, study population, surveillance exposure, and analytical method. These are cumulative probabilities across a defined age range, not annual risks or predictions that a particular carrier will develop cancer.\n\nLynch-associated colorectal cancers often arise earlier than sporadic cases and are relatively enriched in the proximal, or right-sided, colon. Neither feature is obligatory: cancers occur throughout the colon and rectum, and some carriers first develop cancer at older ages. Multiple primary colorectal cancers may occur simultaneously or years apart. The underlying precursor is often an adenoma, but the syndrome usually does not produce the dense polyposis characteristic of familial adenomatous polyposis. Some pathways may involve mismatch repair-deficient crypts before an obvious conventional adenoma develops.\n\nEndometrial cancer is another major manifestation and may precede colorectal cancer. Its cumulative risk is substantial in MLH1, MSH2, and MSH6 carriers, with many estimates falling broadly between 30% and 60% by late adulthood. The risk associated with PMS2 is lower. Endometrial cancer originates in the uterine lining and is biologically distinct from cervical cancer; grouping both under “uterine cancer” can conceal important differences in family histories.\n\nOther established associations include ovarian cancer, stomach cancer, cancer of the small intestine, upper urinary tract urothelial cancer, biliary tract cancer, and pancreatic cancer. Some brain tumors, particularly gliomas, also occur within the spectrum. Upper urinary tract cancer refers especially to the urothelial lining of the renal pelvis and ureter, rather than the usual forms of renal-cell cancer. Several extracolonic risks are particularly prominent with MSH2, whereas PMS2 generally has a more restricted, lower-risk phenotype.\n\nSebaceous adenomas, sebaceous carcinomas, and certain keratoacanthomas can form part of the Muir–Torre phenotype. These skin findings may provide a clue to an underlying repair defect, although not every sebaceous tumor indicates Lynch syndrome. The historical term “Turcot syndrome” has been used for associations between intestinal tumors and brain tumors, but encompasses more than one genetic disorder and does not identify a single mechanism.\n\nEvidence also supports increased prostate cancer risk in some Lynch syndrome groups, particularly MSH2 carriers. By contrast, the degree to which breast cancer belongs to the syndrome remains less certain, and it is not generally treated as a defining cancer. A cancer occurring in a carrier is not automatically caused by Lynch syndrome; ordinary sporadic cancers can occur in the same person."
    },
    {
      "heading": "Tumor screening and diagnostic confirmation",
      "text": "Modern identification frequently begins with testing a newly diagnosed colorectal or endometrial tumor rather than selecting patients solely by age or family history. Many professional frameworks support universal tumor screening in these cancer types because inherited predisposition can be present without an obvious pedigree. Tumor testing is a case-finding step: it identifies repair abnormalities that may warrant further investigation, but does not by itself establish an inherited diagnosis.\n\nImmunohistochemistry examines whether the tumor expresses MLH1, PMS2, MSH2, and MSH6 proteins. Their partnership explains characteristic staining patterns. Loss of MLH1 commonly leads to loss of PMS2, while loss of MSH2 commonly leads to loss of MSH6. Isolated PMS2 or MSH6 loss can therefore help direct genetic investigation. Interpretation requires adequate internal positive controls, because poor fixation, technical problems, treatment effects, or heterogeneous staining can complicate the result. Some pathogenic variants produce a nonfunctional protein that remains detectable by staining.\n\nMSI testing measures instability at selected repetitive DNA markers, using polymerase chain reaction or sequencing-based methods. It provides evidence about repair function rather than directly identifying an inherited variant. Immunohistochemistry and MSI testing are highly informative but not perfectly concordant; some tumors, including particular MSH6-associated tumors, may produce less obvious instability on certain assays. Results are interpreted alongside tumor type, tissue quality, and the characteristics of the testing platform.\n\nWhen a colorectal tumor shows loss of MLH1 and PMS2, testing for MLH1 promoter methylation helps identify a common sporadic mechanism. A tumor BRAF V600E variant can also support a sporadic explanation in this setting, although it is not an absolute exclusion test. BRAF testing does not have the same triage role in endometrial cancer. Age, family history, and unusual findings may still justify investigation for rare constitutional mechanisms.\n\nConfirmation usually rests on finding a pathogenic or likely pathogenic constitutional variant through genetic testing, commonly using blood or another non-tumor specimen. Multigene panels can identify alternative inherited cancer syndromes as well as Lynch syndrome. Testing must detect relevant deletions and duplications in addition to small sequence changes. PMS2 analysis is technically challenging because highly similar pseudogene sequences can interfere with some methods.\n\nA variant of uncertain significance does not establish Lynch syndrome and is not equivalent to a pathogenic result. Where tumor mismatch repair deficiency remains unexplained after constitutional testing, paired tumor–normal analysis may reveal two acquired repair-gene alterations. Such “double-somatic” tumors can resemble inherited disease. The term “Lynch-like syndrome” has been used for unresolved cases, but describes a heterogeneous testing category rather than one established inherited disorder."
    },
    {
      "heading": "Inheritance, family investigation, and related disorders",
      "text": "Lynch syndrome generally follows autosomal dominant inheritance. A person carrying a heterozygous pathogenic variant has a 50% probability of transmitting that variant in each pregnancy, regardless of the child’s sex. Each transmission event is independent. Inheriting the variant is distinct from developing cancer: penetrance is incomplete, and cancer site and age of onset cannot be inferred precisely from the variant alone.\n\nA family history can therefore appear to skip a generation even when the variant has been transmitted. One carrier may remain cancer-free into old age, while a child develops cancer relatively young. Family size, the number of relatives with a uterus or ovaries, access to medical records, and historical diagnostic terminology also affect the apparent pattern. Environmental exposures and additional genetic factors may modify risk, but most do not yet support sufficiently precise individual prediction.\n\nGenetic counseling addresses the distinction between a tumor result and an inherited finding, the possible outcomes of testing, and implications for relatives. Once a specific familial pathogenic variant has been established, relatives can undergo targeted testing for that variant. This process, called cascade testing, is more straightforward than initiating a broad search in each family member. A relative who tests negative for a known familial variant has not inherited that particular Lynch syndrome predisposition, although unrelated personal or familial risks can remain.\n\nA negative result has a different meaning when no causal variant has been identified in the family. It may be uninformative rather than reassuring, particularly when testing was incomplete or the family pattern remains unexplained. Conversely, increasingly broad panels identify uncertain variants and incidental findings that require careful separation from the original clinical question. Variant classifications can change as additional evidence accumulates.\n\nRarely, a person inherits pathogenic variants affecting both copies of the same mismatch repair gene. This causes constitutional mismatch repair deficiency, a distinct, usually childhood-onset disorder. It is associated with brain tumors, blood cancers, and gastrointestinal malignancies, often with café-au-lait-like skin pigmentation. Parents may each have heterozygous Lynch syndrome, sometimes without a striking cancer history, especially with PMS2. This condition should not be described simply as an unusually severe presentation of ordinary heterozygous Lynch syndrome.\n\nFamily investigation also raises questions involving data privacy, communication, and reproductive medicine. Legal protections concerning genetic information differ among jurisdictions and may distinguish health insurance from life or disability insurance. Prenatal testing and preimplantation genetic testing are technically possible when the familial variant is known. Their use involves reproductive and ethical considerations separate from estimating cancer risk, particularly because Lynch syndrome has variable penetrance and usually manifests in adulthood."
    },
    {
      "heading": "Surveillance and early detection",
      "text": "Colonoscopy is the central established surveillance procedure in Lynch syndrome. It allows direct inspection of the colon and removal of precancerous lesions during the same examination. Long-term observational studies and controlled family-based research have associated organized colonoscopic surveillance with reductions in colorectal cancer incidence and mortality. Its role is preventive as well as diagnostic, unlike a test that merely detects an already established cancer.\n\nSurveillance schedules differ among professional guidelines and increasingly distinguish the causal gene. Many frameworks begin colonoscopy around ages 20–25 for MLH1 and MSH2 carriers, with later starts often used for MSH6 and PMS2. Intervals commonly range from one to three years, depending on the gene and guideline. Earlier cancer in a family and previous neoplasia can affect the schedule. These ranges describe clinical policy rather than one universally accepted protocol.\n\nColorectal cancers nevertheless occur between surveillance examinations. Explanations include missed lesions, incomplete removal, flat or subtle precursors, and biological pathways that may progress differently from the conventional adenoma–carcinoma sequence. Bowel preparation, complete examination, endoscopist performance, and adherence all influence effectiveness. Surveillance studies must therefore distinguish the intrinsic cancer risk associated with a variant from outcomes under a particular surveillance program.\n\nFor endometrial cancer, abnormal uterine bleeding is an important presenting feature, but the benefits of screening asymptomatic carriers are less firmly established than those of colonoscopy. Endometrial biopsy can detect some precancerous changes and cancers, while transvaginal ultrasonography has limitations, particularly before menopause when endometrial thickness changes normally. Periodic endometrial sampling appears in several clinical frameworks, but convincing evidence of reduced mortality remains limited. Screening for ovarian cancer with ultrasound or serum markers has not demonstrated reliable effectiveness in this population.\n\nUpper gastrointestinal surveillance is more variable. Some programs use upper endoscopy, particularly in selected gene groups, families with gastric cancer, or populations with higher background gastric cancer incidence. Testing for and treating Helicobacter pylori infection may be incorporated because the organism is an established gastric carcinogen. However, age thresholds, intervals, and the magnitude of benefit are not settled uniformly across guidelines.\n\nEvidence is still more limited for routine surveillance of the urinary tract, pancreas, brain, and other less commonly affected sites. Pancreatic surveillance is generally confined to selected high-risk settings and specialist programs, often incorporating family history. Urine-based screening has uncertain sensitivity and outcome benefits. The association of an organ with Lynch syndrome therefore does not automatically imply that an effective screening program exists for it."
    },
    {
      "heading": "Risk-reducing interventions and chemoprevention",
      "text": "Risk reduction in Lynch syndrome includes removal of precursor lesions, selected preventive operations, and pharmacological approaches. These interventions differ in the strength of their supporting evidence and in their effects on organ function, fertility, and long-term health. Studies also distinguish primary prevention in an unaffected carrier from prevention of a second cancer after treatment of a first malignancy.\n\nThe strongest randomized evidence for a preventive medication concerns aspirin. In the CAPP2 randomized controlled trial, 861 participants with Lynch syndrome were assigned to 600 mg aspirin daily or placebo. Long-term follow-up showed a reduction in colorectal cancer among those assigned aspirin, with the benefit emerging only after a delay of several years. In the intention-to-treat analysis reported after approximately ten years of follow-up, the hazard ratio for colorectal cancer was about 0.65. Analyses incorporating treatment exposure also supported benefit, particularly among participants who had taken treatment for at least two years.\n\nThe CAPP2 findings do not establish that its trial dose is optimal for every carrier. Dose, duration, age at initiation, and gene-specific benefit have remained subjects of investigation. Aspirin can cause gastrointestinal bleeding and other adverse effects, and the balance between preventive benefit and harm varies among individuals. Its anticancer mechanism may involve inflammatory signaling, platelet biology, and effects on tumor–host interactions; no single mechanism fully accounts for the delayed clinical effect.\n\nRemoval of the uterus prevents subsequent endometrial cancer arising in that organ. Removal of both fallopian tubes and ovaries reduces ovarian cancer risk but also causes loss of ovarian function when performed before natural menopause. Risk-reducing gynecological surgery is therefore considered separately by organ, gene, age, and reproductive circumstances. The ovarian risk associated with PMS2, for example, is not equivalent to that associated with MSH2. Evidence supporting hysterectomy as effective endometrial cancer prevention is stronger than evidence that surveillance provides the same protection.\n\nRemoving an unaffected colon solely because of a Lynch syndrome variant is not routine practice when high-quality colonoscopic surveillance is feasible. Once colorectal cancer has developed, however, the extent of bowel resection becomes a related prevention question: retaining more colon preserves function but leaves more tissue at risk for a later primary cancer. Such decisions involve both cancer treatment and long-term risk reduction.\n\nSmoking, excess body weight, and alcohol exposure are relevant to general cancer risk, but observational associations do not establish a precise Lynch-specific preventive effect for every behavioral factor. Experimental strategies include vaccines directed against shared frameshift-derived tumor antigens. These approaches aim to generate immune responses before invasive cancer develops, but preventive vaccination for Lynch syndrome remains investigational rather than an established substitute for surveillance."
    },
    {
      "heading": "Treatment of Lynch-associated cancers",
      "text": "Lynch-associated cancers are treated according to their anatomical site, stage, molecular characteristics, and the person’s clinical condition. The inherited diagnosis can influence the extent of surgery, interpretation of tumor tests, and planning for subsequent cancer risks, but it does not replace standard staging. A carrier may also develop a mismatch repair-proficient tumor, so treatment-relevant biomarkers are assessed in the cancer itself rather than assumed from constitutional status alone.\n\nFor colon cancer, segmental resection removes the affected portion of bowel, while more extensive colectomy removes a larger amount of tissue at risk. More extensive surgery lowers the probability of a subsequent cancer in the remaining colon but can increase stool frequency and alter bowel function. Observational evidence indicates that the balance differs by gene: the long-term metachronous colorectal cancer risk is generally greater for MLH1 and MSH2 than for MSH6 or PMS2. Rectal cancer introduces additional considerations involving pelvic anatomy, continence, and the consequences of different operations.\n\nMismatch repair status also affects interpretation of chemotherapy evidence. Localized stage II mismatch repair-deficient colon cancers generally have a favorable stage-specific prognosis and have not shown the same benefit from fluoropyrimidine-only adjuvant treatment as mismatch repair-proficient tumors. This does not mean that all chemotherapy is ineffective. Stage III disease is commonly treated with regimens containing oxaliplatin and a fluoropyrimidine, and evidence is interpreted according to stage and regimen rather than through a blanket rule about repair deficiency.\n\nThe largest therapeutic change has come from immune checkpoint inhibitors. Mismatch repair-deficient or MSI-high cancers can generate numerous abnormal peptides recognized by T cells, while exploiting inhibitory signaling pathways to escape immune attack. Drugs blocking PD-1, sometimes combined with other checkpoint agents, can restore antitumor activity. In 2017, the United States approved pembrolizumab for certain previously treated unresectable or metastatic MSI-high or mismatch repair-deficient solid tumors irrespective of their site of origin, an important biomarker-defined approval.\n\nIn metastatic colorectal cancer, the KEYNOTE-177 trial established pembrolizumab as an effective first-line option for MSI-high or mismatch repair-deficient disease, with longer progression-free survival than the chemotherapy comparator. Checkpoint therapy is also important in advanced endometrial cancer, where treatment selection increasingly incorporates repair status. Benefits depend on the clinical setting, and immune-related toxicities can affect organs including the bowel, liver, lungs, and endocrine glands.\n\nStudies of preoperative immunotherapy have produced striking pathological responses in selected localized mismatch repair-deficient colorectal cancers. Small studies in locally advanced rectal cancer have also reported complete clinical responses that permitted nonoperative management under intensive assessment. These results do not establish identical outcomes for every tumor or eliminate questions about long-term durability, resistance, and optimal surveillance. Whether repair deficiency is inherited or acquired remains essential for family investigation, but the tumor’s molecular phenotype is often the more immediate determinant of checkpoint-treatment eligibility."
    }
  ],
  "links": [
    "cancer",
    "dna-mismatch-repair",
    "colorectal-cancer",
    "epidemiology",
    "dna",
    "gene",
    "mutation",
    "microsatellite-instability",
    "immune-system",
    "cancer-immunotherapy",
    "tumor-mutational-burden",
    "stomach-cancer",
    "small-intestine",
    "pancreatic-cancer",
    "prostate-cancer",
    "breast-cancer",
    "immunohistochemistry",
    "autosomal-dominant-inheritance",
    "data-privacy",
    "biopsy",
    "ultrasonography",
    "aspirin",
    "randomized-controlled-trial",
    "menopause",
    "surgery",
    "chemotherapy",
    "immune-checkpoint-inhibitor",
    "t-cell"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}